By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Antabio 

436 Rue Pierre et Marie Curie

Labège    31670  France
Phone: n/a Fax: n/a


SEARCH JOBS

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: (i) a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and (ii) a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval by 2021. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. The Company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies.

YEAR FOUNDED:

2009

LEADERSHIP:

Founder and CEO: Marc Lemonnier

CSO: Martin Everett

JOBS:

Please click here for Antabio job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW ANTABIO:



Key Statistics


Email:
Ownership: Private

Web Site: Antabio
Employees:
Symbol: 
 









Company News
//-->